Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Stephen C. Piscitelli; William D. Figg; Barbara Hahn; Grace Kelly; Steven Thomas; Robert E. Walker

doi:10.1128/aac.41.12.2797

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Stephen C. Piscitelli^*
, William D. Figg
, Barbara Hahn
, Grace Kelly
, Steven Thomas
, Robert E. Walker

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Comment/debate

50 Scopus citations

Abstract

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

Original language	English
Pages (from-to)	2797-2799
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	41
Issue number	12
DOIs	https://doi.org/10.1128/aac.41.12.2797
State	Published - Dec 1997

Access to Document

10.1128/aac.41.12.2797

Cite this

@article{2bd28190a5a94b5896813179046d1ce4,

title = "Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients",

abstract = "The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.",

author = "Piscitelli, \{Stephen C.\} and Figg, \{William D.\} and Barbara Hahn and Grace Kelly and Steven Thomas and Walker, \{Robert E.\}",

year = "1997",

month = dec,

doi = "10.1128/aac.41.12.2797",

language = "English",

volume = "41",

pages = "2797--2799",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

AU - Piscitelli, Stephen C.

AU - Figg, William D.

AU - Hahn, Barbara

AU - Kelly, Grace

AU - Thomas, Steven

AU - Walker, Robert E.

PY - 1997/12

Y1 - 1997/12

N2 - The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

AB - The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

UR - https://www.scopus.com/pages/publications/0030784668

U2 - 10.1128/aac.41.12.2797

DO - 10.1128/aac.41.12.2797

M3 - Comment/debate

C2 - 9420064

AN - SCOPUS:0030784668

SN - 0066-4804

VL - 41

SP - 2797

EP - 2799

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 12

ER -

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Abstract

Access to Document

Fingerprint

Cite this